Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Endo Gets Untitled Letter for Omitting Heart Risks in Brochure for Prostate Cancer Drug

Drug Industry Daily

Sept. 28, 2012 | Vol. 11 No. 191

Endo Gets Untitled Letter for Omitting Heart Risks in Brochure for Prostate Cancer Drug

Endo Pharmaceuticals received an FDA untitled letter for omitting cardiovascular (CV) and other serious risks associated with its prostate cancer drug Vantas in a 12-page caregiver brochure.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Report Pokes Holes in FDA Celexa Dose Warning Report Pokes Holes In FDA Celexa Dose Warning Report Pokes Holes in FDA Celexa Dosing Warning FDA Issues Safety Alerts on Botox, Hospira and Potiga

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.